- Home
- PHAT vs MGIC Comparison
PHAT vs MGIC Comparison
Compare PHAT & MGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAT | MGIC |
|---|---|---|
| Founded | 2018 | 1983 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 942.6M | 990.3M |
| IPO Year | 2019 | 1991 |
Fundamental Metrics
Financial Performance| Metric | PHAT | MGIC |
|---|---|---|
| Price | $14.36 | $25.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $17.33 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 828.8K | 43.7K |
| Earning Date | 10-30-2025 | 11-18-2025 |
| Dividend Yield | N/A | ★ 2.38% |
| EPS Growth | N/A | ★ 16.15 |
| EPS | N/A | ★ 0.81 |
| Revenue | $147,190,000.00 | ★ $603,216,000.00 |
| Revenue This Year | $218.59 | $12.87 |
| Revenue Next Year | $84.38 | $6.23 |
| P/E Ratio | ★ N/A | $31.55 |
| Revenue Growth | ★ 460.30 | 12.65 |
| 52 Week Low | $2.21 | $11.36 |
| 52 Week High | $16.27 | $26.00 |
Technical Indicators
Market Signals| Indicator | PHAT | MGIC |
|---|---|---|
| Relative Strength Index (RSI) | 49.05 | 68.58 |
| Support Level | $14.12 | $24.87 |
| Resistance Level | $16.27 | $26.00 |
| Average True Range (ATR) | 0.72 | 0.80 |
| MACD | -0.12 | 0.18 |
| Stochastic Oscillator | 8.39 | 90.81 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.